Action HRTX HERON THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Heron Therapeutics, Inc.

Actions

HRTX

US4277461020

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 26/04/2024 		Varia. 5j. Varia. 1 janv.
2,45 USD -3,92 % Graphique intraday de Heron Therapeutics, Inc. -7,20 % +44,12 %
23/04 HERON THERAPEUTICS, INC. : Capital One Securities reste à l'achat ZM
21/03 Heron Therapeutics, Inc. annonce des changements au sein de sa direction, avec effet au 29 mars 2024 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024
Heron Therapeutics : Q4 2023 Earnings Call Presentation
Health Care Down on Rotation to Rate-Sensitive Sectors -- Health Care Roundup
Sector Update: Health Care Stocks Slipping Late Afternoon
Heron Therapeutics Shares Soar After Q4 Results Beat
Heron Therapeutics : Q4 2023 Earnings Call Presentation
Heron Therapeutics: Q4 Earnings Snapshot
Heron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Earnings Flash (HRTX) HERON THERAPEUTICS Posts Q4 Revenue $34.2M, vs. Street Est of $31.2M
Heron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024
Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024
Heron Therapeutics Shares Rise 15% After FDA Approves Expanded Use of Zynrelef
Heron Therapeutics Announces FDA Approval of ZYNRELEF Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
Heron Therapeutics Says FDA Approved Expanded Label for Zynrelef to Add More Orthopedic, Soft Tissue Procedures
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action HRTX
  4. Actualités Heron Therapeutics, Inc.
  5. Autres langues